| ID | 1237 |
| Name of the vaccine | VPM1002 |
| Microbe | Bacteria |
| Disease name | Pulmonary Tuberculosis (TB) |
| Name of bacteria | Mycobacterium tuberculosis |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 18 to 65 years |
| Description of the vaccine | Recombinant BCG vaccine from the Mycobacterium bovis BCG subtype Prague. |
| Name of the manufacturer | Serum Institute of India Pvt. Ltd. |
| Name of the manufacturing country | Bangladesh, India |
| Year of manufacture | 2022 |
| Clinical Phase status | Clinical - Phase 2, Phase 3 |
| Bacterial strain | Acid-fast Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | Lyophilized |
| Dosage | Single dose. |
| Mechanism of action | NA |
| Route of administration | Intradermal |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03152903 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|